Cellution Biologics, Inc., a leader in regenerative allograft solutions, proudly announces the publication of its first peer-reviewed clinical article, “Bridging the Wound Gap: Interim Results from ...
When treated with KRAS inhibitors alone, cancer cells can escape destruction by using the salvage pathway to gather additional nucleosides to repair the DNA damage. Combining TRE-515 with KRAS ...
Paris – December 16, 2025 - EUROAPI announced today that its main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend further the duration of their lock-up until December 18, 2026, subject ...
Orchard Therapeutics, a Kyowa Kirin company, today celebrates the addition of metachromatic leukodystrophy (MLD) to the U.S. Recommended Uniform Screening Panel (RUSP), a national guideline comprising ...
Tiny Health and Bristle Health are recruiting participants for a pioneering research study examining the connection between oral and gut health. The study offers participants comprehensive microbiome ...
The McKnight’s Pinnacle Awards recognize sector veterans with 20 or more years of service who have set new standards, driven innovation and inspired colleagues across the senior care, skilled nursing ...
In addition to individual visits, the company has introduced its CarePass program: a pre-paid option offering 8 visits for $180. This package averages $15 per visit and includes appropriate ...
Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing ...
As announced on 9 October 2025, TACTI-004 had enrolled the necessary 170 patients to conduct the futility analysis that remains on track for the first quarter of CY2026. Furthermore, Immutep expects ...
Mr. Gruntfest is a seasoned healthcare executive with over 20 years of experience spanning reimbursement management, payer solutions, and patient support programs. He currently serves as Managing ...
Under the agreement, Ionetix will provide Cellectar with a reliable, clinical and commercial-scale supply of cGMP-grade Ac-225 and At-211 to support its drug development programs through clinical ...
Laru-zova is investigational and has not been approved by FDA for use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback